Infigratinib

Drug identity checked against registry records

Also recorded as BBP-831; BGJ398

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaNCT06206278LianBio LLCPhase 2Terminated2024-05-31Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.